REDEFINE-1: Phase 3 Pivotal Trial (NCT05064293) Study Title: "Efficacy and Safety of CagriSema in Adults With Overweight or Obesity (REDEFINE 1)" Status: Completed (Results Published 2024) Phase: Phase 3 Enrollment: 3,400+ participants Study Period: 2021-2024 Location: Global, 15+ countries Design: Randomized, double-blind, active-controlled Duration: 68 weeks Intervention: CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) vs
Aids Digestion & Metabolism: Dandelion Root and Ayurvedic herbs support digestion, reduce bloating and promote nutrient absorption
assessed the eryptotic properties of selected BFRs in human erythrocytes: TBBPA and TBBPS, and the bromophenols 2,4-dibromophenol (2,4-DBP), 2,4,6-tribromophenol (2,4,6-TBP), and pentabromophenol (PBP)
Without published details on the animal study design, sample sizes, dosing protocols, and statistical analyses, it is difficult to assess the robustness of these findings
Sometimes nausea (a common GLP-1 side effect) can make solid food less appealing, so try a high-protein smoothie